相似文献
1
Determination of the primary target of a quinolone drug and the effect of quinolone resistance-conferring mutations by measuring quinolone sensitivity based on its mode of action.
Antimicrob Agents Chemother. 2007 Sep;51(9):3410-2. doi: 10.1128/AAC.00362-07. Epub 2007 Jul 2.
2
A fluoroquinolone-resistant Escherichia coli clinical isolate without quinolone resistance-determining region mutations found in Japan.
Antimicrob Agents Chemother. 2011 Aug;55(8):3964-5. doi: 10.1128/AAC.00532-11. Epub 2011 Jun 13.
3
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
J Infect Chemother. 2001 Sep;7(3):191-4. doi: 10.1007/s101560100034.
4
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. doi: 10.1128/AAC.00158-07. Epub 2007 May 14.
5
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Antimicrob Agents Chemother. 2005 May;49(5):1949-56. doi: 10.1128/AAC.49.5.1949-1956.2005.
6
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28.
7
Apigenin as an anti-quinolone-resistance antibiotic.
Int J Antimicrob Agents. 2015 Dec;46(6):666-73. doi: 10.1016/j.ijantimicag.2015.09.006. Epub 2015 Oct 22.
8
Comparison of Mismatch Amplification Mutation Assay PCR and PCR-Restriction Fragment Length Polymorphism for Detection of Major Mutations in gyrA and parC of Escherichia coli Associated with Fluoroquinolone Resistance.
Microb Drug Resist. 2019 Jan/Feb;25(1):23-31. doi: 10.1089/mdr.2017.0351. Epub 2018 Jul 23.
9
Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
Int J Antimicrob Agents. 2019 Mar;53(3):318-324. doi: 10.1016/j.ijantimicag.2018.12.004. Epub 2018 Dec 21.
10
Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
J Antimicrob Chemother. 2006 Dec;58(6):1283-6. doi: 10.1093/jac/dkl388. Epub 2006 Sep 26.
引用本文的文献
1
The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
Molecules. 2016 Mar 28;21(4):268. doi: 10.3390/molecules21040268.
2
Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site.
Biochim Biophys Acta. 2016 Mar;1860(3):569-75. doi: 10.1016/j.bbagen.2015.12.019. Epub 2015 Dec 23.
3
Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV.
Biochemistry. 2014 Sep 2;53(34):5558-67. doi: 10.1021/bi500682e. Epub 2014 Aug 21.
4
Mechanism of quinolone action and resistance.
Biochemistry. 2014 Mar 18;53(10):1565-74. doi: 10.1021/bi5000564. Epub 2014 Mar 7.
5
Two forms of ribosomal protein L2 of Escherichia coli that inhibit DnaA in DNA replication.
Nucleic Acids Res. 2011 May;39(10):4180-91. doi: 10.1093/nar/gkq1203. Epub 2011 Feb 2.
6
Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.
Eur J Pharmacol. 2009 Jan 14;602(2-3):223-9. doi: 10.1016/j.ejphar.2008.11.044. Epub 2008 Dec 3.
本文引用的文献
1
Fluoroquinolones: action and resistance.
Curr Top Med Chem. 2003;3(3):249-82. doi: 10.2174/1568026033452537.
2
Staphylococcus aureus gyrase-quinolone-DNA ternary complexes fail to arrest replication fork progression in vitro. Effects of salt on the DNA binding mode and the catalytic activity of S. aureus gyrase.
J Biol Chem. 2003 Mar 7;278(10):8861-8. doi: 10.1074/jbc.M209207200. Epub 2002 Dec 23.
3
The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions.
Biochemistry. 2002 Oct 1;41(39):11779-85. doi: 10.1021/bi026352v.
4
Cellular roles of DNA topoisomerases: a molecular perspective.
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40. doi: 10.1038/nrm831.
5
DNA topoisomerases: structure, function, and mechanism.
Annu Rev Biochem. 2001;70:369-413. doi: 10.1146/annurev.biochem.70.1.369.
6
Tumor cell death induced by topoisomerase-targeting drugs.
Annu Rev Pharmacol Toxicol. 2001;41:53-77. doi: 10.1146/annurev.pharmtox.41.1.53.
7
The mechanism of inhibition of topoisomerase IV by quinolone antibacterials.
J Biol Chem. 1998 Oct 16;273(42):27668-77. doi: 10.1074/jbc.273.42.27668.
8
DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):29-43. doi: 10.1016/s0167-4781(98)00126-2.
9
Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
J Biol Chem. 1998 Jul 10;273(28):17643-50. doi: 10.1074/jbc.273.28.17643.
10
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
Zotero 插件